Berenberg Starts Axsome Therapeutics (AXSM) at Buy

Berenberg analyst Esther Hong initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target of $112.00.

The analyst commented, "Our Buy recommendation for Axsome Therapeutics reflects two near-term catalysts. First, the FDA will announce its decision on approval of Axsome’s lead product, AXS-05 for the treatment of major depressive disorder, in August. Second, the company expects to submit a new drug application with the FDA this quarter for a second product, AXS-07 for the treatment of migraine."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $63.50 yesterday.

You May Also Be Interested In

• UPDATE: Wolfe Research Starts ironSource Ltd. (IS) at Peerperform
• UPDATE: Wolfe Research Starts The Trade Desk (TTD) at Peerperform
• UPDATE: Wolfe Research Starts Procore Technologies, Inc (PCOR) at Peerperform